Moderna Inc saw a sharp uptick in its share price after news of a Hantavirus outbreak tied to the cruise vessel MV Hondius. The stock rose roughly 13% over several trading sessions as investors reacted to reports that the Andes strain of Hantavirus infected about 10 people on board, resulting in three deaths.
Despite the market reaction, Bernstein Global Research published a note that tamped down expectations for a wide-scale public health emergency. The firm reiterated a Market-Perform rating on Moderna with a price target of $45.00 - a level that implies about a 17% downside from Moderna’s May 8 closing price of $54.35.
Bernstein highlighted key features of the current situation. While most Hantavirus infections arise from direct exposure to rodent saliva, feces, or urine, the Andes strain has documented human-to-human transmission. The disease presentation of greatest concern is Hantavirus Cardio-Pulmonary Syndrome, which carries a mortality rate reported in the range of 30% to 40%.
That clinical severity notwithstanding, Bernstein’s analysts argued that the pattern and scope of transmission seen so far are unlikely to trigger a pandemic on the scale of COVID-19. As they put it, "We don’t see this as the next 'pandemic' & think this Hantavirus related trade should fade from current highs." The firm emphasized the localized character of the incident as a counterpoint to broader contagion scenarios.
From a development perspective, Moderna retains technical capabilities to pivot toward a Hantavirus countermeasure given the scalability of its messenger RNA platform. The company is reported to have ongoing research collaborations with Korea University’s Vaccine Innovation Center and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). Bernstein’s assessment, however, is that those partnerships remain at the preclinical stage.
On the vaccine landscape, the analysts noted that some older, short-term vaccines exist in Asian markets for Hemorrhagic Fever with Renal Syndrome (HFRS), but there are currently no globally approved commercial vaccines for the more lethal HCPS form. Creating a broadly protective multi-strain vaccine would require the full clinical development pathway - phase 1 through phase 3 trials - with development costs estimated to exceed $500 million.
Bernstein also outlined the commercial outlook policymakers and manufacturers might expect. Rather than a consumer-facing product with mass-market demand, the firm projects that potential revenue would more likely arise from government procurement programs - sustained funding for stockpiles and pandemic preparedness initiatives - rather than large-scale retail uptake.
Summary
Moderna’s shares climbed about 13% after an outbreak of the Andes strain of Hantavirus aboard the MV Hondius infected roughly 10 people and caused three deaths. Bernstein Global Research maintains a Market-Perform rating and a $45.00 price target, arguing a global pandemic is unlikely and noting Moderna’s Hantavirus-related work is preclinical. Vaccine development for the lethal HCPS presentation would be expensive and commercially oriented toward government stockpiling.